The DOI matches its Crossref record; 115 of the 115 references it cites were found in a registry or an index.
Molecular Characterization of Epithelial Ovarian Cancer: Implications for Diagnosis and Treatment
Open accessAbstract
Epithelial ovarian cancer is a highly heterogeneous disease characterized by multiple histological subtypes. Molecular diversity has been shown to occur within specific histological subtypes of epithelial ovarian cancer, between different tumors of an individual patient, as well as within individual tumors. Recent advances in the molecular characterization of epithelial ovarian cancer tumors have provided the basis for a simplified classification scheme in which these cancers are classified as either type I or type II tumors, and these two categories have implications regarding disease pathogenesis and prognosis. Molecular analyses, primarily based on next-generation sequencing, otherwise known as high-throughput sequencing, are allowing for further refinement of ovarian cancer classification, facilitating the elucidation of the site(s) of precursor lesions of high-grade serous ovarian cancer, and providing insight into the processes of clonal selection and evolution that may be associated with development of chemoresistance. Potential therapeutic targets have been identified from recent molecular profiling studies of these tumors, and the effectiveness and safety of a number of specific targeted therapies have been evaluated or are currently being studied for the treatment of women with this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Integrated genomic analyses of ovarian carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/hvp3-wg08 · Cited by 7,925
Greaves, M., & Maley, C. C. (2012) · Nature · doi:10.1038/nature10762 · Cited by 3,162
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mirza, M. R., Monk, B. J., Herrstedt, J., Oza, A. M., Mahner, S., Redondo, A., Fabbro, M., Ledermann, J. A., Lorusso, D., Vergote, I., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611310 · Cited by 2,451
A Phase 3 Trial of Bevacizumab in Ovarian Cancer
Perren, T. J., Swart, A. M., Pfisterer, J., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., Kurzeder, C., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103799 · Cited by 2,172
ARID1A Mutations in Endometriosis-Associated Ovarian Carcinomas
Wiegand, K. C., Shah, S. P., Al-Agha, O. M., Zhao, Y., Tse, K., Zeng, T., Senz, J., McConechy, M. K., Anglesio, M. S., Kalloger, S. E., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1008433 · Cited by 1,712 · cited 1×
“For example, a number of studies have revealed a high frequency of inactivating mutations in ARID1A (a tumor suppressor gene involved in chromatin remodeling) in ovarian clear cell carcinomas [26,27], and amplification of ERBB2 (gene encoding for HER2) in 19% and 14% were reported in mucinous tumors and clear cell car…”
BackgroundOlaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
Kaufman, B., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., Hubert, A., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.56.2728 · Cited by 1,671
Pujade-Lauraine, E., Hilpert, F., Weber, B., Reuss, A., Poveda, A., Kristensen, G., Sorio, R., Vergote, I., Witteveen, P., Bamias, A., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.51.4489 · Cited by 1,622
Whole–genome characterization of chemoresistant ovarian cancer
Patch, A.-M., Christie, E. L., Etemadmoghadam, D., Garsed, D. W., George, J., Fereday, S., Nones, K., Cowin, P., Alsop, K., Bailey, P. J., et al. (2015) · Nature · doi:10.1038/nature14410 · Cited by 1,569
Novel Molecular Subtypes of Serous and Endometrioid Ovarian Cancer Linked to Clinical Outcome
Tothill, R. W., Tinker, A. V., George, J., Brown, R., Fox, S. B., Lade, S., Johnson, D. S., Trivett, M. K., Etemadmoghadam, D., Locandro, B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0196 · Cited by 1,467
Aghajanian, C., Blank, S. V., Goff, B. A., Judson, P. L., Teneriello, M. G., Husain, A., Sovak, M. A., Yi, J., & Nycum, L. R. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.42.0505 · Cited by 1,384
Buys, S. S. (2011) · JAMA · doi:10.1001/jama.2011.766 · Cited by 1,323
Frequent Mutations of Chromatin Remodeling Gene ARID1A in Ovarian Clear Cell Carcinoma
Jones, S., Wang, T.-L., Shih, I.-M., Mao, T.-L., Nakayama, K., Roden, R., Glas, R., Slamon, D., Diaz, L. A., Vogelstein, B., et al. (2010) · Science · doi:10.1126/science.1196333 · Cited by 1,219
Hamanishi, J., Mandai, M., Ikeda, T., Minami, M., Kawaguchi, A., Murayama, T., Kanai, M., Mori, Y., Matsumoto, S., Chikuma, S., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.3397 · Cited by 1,180
Molecular pathogenesis and extraovarian origin of epithelial ovarian cancer—Shifting the paradigm
Kurman, R. J., & Shih, I.-M. (2011) · Human Pathology · doi:10.1016/j.humpath.2011.03.003 · Cited by 1,073
Pennington, K. P., Walsh, T., Harrell, M. I., Lee, M. K., Pennil, C. C., Rendi, M. H., Thornton, A., Norquist, B. M., Casadei, S., Nord, A. S., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-2287 · Cited by 1,051
Jacobs, I. J., Menon, U., Ryan, A., Gentry-Maharaj, A., Burnell, M., Kalsi, J. K., Amso, N. N., Apostolidou, S., Benjamin, E., Cruickshank, D., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01224-6 · Cited by 1,048
The Dualistic Model of Ovarian Carcinogenesis
Kurman, R. J., & Shih, I.-M. (2016) · The American Journal of Pathology · doi:10.1016/j.ajpath.2015.11.011 · Cited by 923
Oza, A. M., Cook, A. D., Pfisterer, J., Embleton, A., Ledermann, J. A., Pujade-Lauraine, E., Kristensen, G., Carey, M. S., Beale, P., Cervantes, A., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00086-8 · Cited by 875
Mutations in BRAF and KRAS Characterize the Development of Low-Grade Ovarian Serous Carcinoma
Singer, G., Oldt, R., Cohen, Y., Wang, B. G., Sidransky, D., Kurman, R. J., & Shih, I.-M. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.6.484 · Cited by 854
Sugiyama, T., Kamura, T., Kigawa, J., Terakawa, N., Kikuchi, Y., Kita, T., Suzuki, M., Sato, I., & Taguchi, K. (2000) · Cancer · doi:10.1002/1097-0142(20000601)88:11<2584::aid-cncr22>3.0.co;2-5 · Cited by 795
Bookman, M. A., Darcy, K. M., Clarke-Pearson, D., Boothby, R. A., & Horowitz, I. R. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.10.104 · Cited by 598
Liu, J. F., Barry, W. T., Birrer, M., Lee, J.-M., Buckanovich, R. J., Fleming, G. F., Rimel, B., Buss, M. K., Nattam, S., Hurteau, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70391-2 · Cited by 585
Prognostically relevant gene signatures of high-grade serous ovarian carcinoma
Verhaak, R. G. W., Tamayo, P., Yang, J.-Y., Hubbard, D., Zhang, H., Creighton, C. J., Fereday, S., Lawrence, M., Carter, S. L., Mermel, C. H., et al. (2012) · Journal of Clinical Investigation · doi:10.1172/jci65833 · Cited by 569
The Histologic Type and Stage Distribution of Ovarian Carcinomas of Surface Epithelial Origin
Seidman, J. D., Horkayne-Szakaly, I., Haiba, M., Boice, C. R., Kurman, R. J., & Ronnett, B. M. (2004) · International Journal of Gynecological Pathology · doi:10.1097/01.pgp.0000101080.35393.16 · Cited by 554
Oza, A. M., Cibula, D., Benzaquen, A. O., Poole, C., Mathijssen, R. H. J., Sonke, G. S., Colombo, N., Špaček, J., Vuylsteke, P., Hirte, H., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71135-0 · Cited by 547
Studying clonal dynamics in response to cancer therapy using high-complexity barcoding
Bhang, H.-E. C., Ruddy, D. A., Krishnamurthy Radhakrishna, V., Caushi, J. X., Zhao, R., Hims, M. M., Singh, A. P., Kao, I., Rakiec, D., Shaw, P., et al. (2015) · Nature Medicine · doi:10.1038/nm.3841 · Cited by 507
McCluggage, W. G. (2011) · Pathology · doi:10.1097/pat.0b013e328348a6e7 · Cited by 497
Frequent Activating Mutations of PIK3CA in Ovarian Clear Cell Carcinoma
Kuo, K.-T., Mao, T.-L., Jones, S., Veras, E., Ayhan, A., Wang, T.-L., Glas, R., Slamon, D., Velculescu, V. E., Kuman, R. J., et al. (2009) · The American Journal of Pathology · doi:10.2353/ajpath.2009.081000 · Cited by 485
Early Events in the Pathogenesis of Epithelial Ovarian Cancer
Landen, C. N., Birrer, M. J., & Sood, A. K. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.9970 · Cited by 462
Janku, F., Wheler, J. J., Westin, S. N., Moulder, S. L., Naing, A., Tsimberidou, A. M., Fu, S., Falchook, G. S., Hong, D. S., Garrido-Laguna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.36.1196 · Cited by 447
Bashashati, A., Ha, G., Tone, A., Ding, J., Prentice, L. M., Roth, A., Rosner, J., Shumansky, K., Kalloger, S., Senz, J., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4230 · Cited by 421
Farley, J., Brady, W. E., Vathipadiekal, V., Lankes, H. A., Coleman, R., Morgan, M. A., Mannel, R., Yamada, S. D., Mutch, D., Rodgers, W. H., et al. (2013) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70572-7 · Cited by 413
Spatial and Temporal Heterogeneity in High-Grade Serous Ovarian Cancer: A Phylogenetic Analysis
Schwarz, R. F., Ng, C. K. Y., Cooke, S. L., Newman, S., Temple, J., Piskorz, A. M., Gale, D., Sayal, K., Murtaza, M., Baldwin, P. J., et al. (2015) · PLOS Medicine · doi:10.1371/journal.pmed.1001789 · Cited by 400
Differences in Tumor Type in Low-stage Versus High-stage Ovarian Carcinomas
Köbel, M., Kalloger, S. E., Huntsman, D. G., Santos, J. L., Swenerton, K. D., Seidman, J. D., & Gilks, C. B. (2010) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0b013e3181c042b6 · Cited by 398
Prognostic and Therapeutic Relevance of Molecular Subtypes in High-Grade Serous Ovarian Cancer
Konecny, G. E., Wang, C., Hamidi, H., Winterhoff, B., Kalli, K. R., Dering, J., Ginther, C., Chen, H.-W., Dowdy, S., Cliby, W., et al. (2014) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dju249 · Cited by 398
Yang, D., Sun, Y., Hu, L., Zheng, H., Ji, P., Pecot, C. V., Zhao, Y., Reynolds, S., Cheng, H., Rupaimoole, R., et al. (2013) · Cancer Cell · doi:10.1016/j.ccr.2012.12.020 · Cited by 394
Origins and molecular pathology of ovarian cancer
Bell, D. A. (2005) · Modern Pathology · doi:10.1016/s0893-3952(22)04456-8 · Cited by 387
Kuhn, E., Kurman, R. J., Vang, R., Sehdev, A. S., Han, G., Soslow, R., Wang, T., & Shih, I. (2012) · The Journal of Pathology · doi:10.1002/path.3023 · Cited by 387
PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies
Lee, J.-M., Ledermann, J. A., & Kohn, E. C. (2014) · Annals of Oncology · doi:10.1093/annonc/mdt384 · Cited by 352
Leijen, S., van Geel, R. M. J. M., Sonke, G. S., de Jong, D., Rosenberg, E. H., Marchetti, S., Pluim, D., van Werkhoven, E., Rose, S., Lee, M. A., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.5942 · Cited by 338
Li, D., Marchenko, N. D., & Moll, U. M. (2011) · Cell Death & Differentiation · doi:10.1038/cdd.2011.71 · Cited by 336
Origin and molecular pathogenesis of ovarian high-grade serous carcinoma
Kurman, R. J. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt463 · Cited by 336
Do, K., Wilsker, D., Ji, J., Zlott, J., Freshwater, T., Kinders, R. J., Collins, J., Chen, A. P., Doroshow, J. H., & Kummar, S. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.4009 · Cited by 322
Aghajanian, C., Goff, B., Nycum, L. R., Wang, Y. V., Husain, A., & Blank, S. V. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.08.004 · Cited by 320
Li, D., Marchenko, N. D., Schulz, R., Fischer, V., Velasco-Hernandez, T., Talos, F., & Moll, U. M. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0534 · Cited by 297
Domchek, S. M., Aghajanian, C., Shapira-Frommer, R., Schmutzler, R. K., Audeh, M. W., Friedlander, M., Balmaña, J., Mitchell, G., Fried, G., Stemmer, S. M., et al. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.12.020 · Cited by 297
Folkins, A. K., Jarboe, E. A., Saleemuddin, A., Lee, Y., Callahan, M. J., Drapkin, R., Garber, J. E., Muto, M. G., Tworoger, S., & Crum, C. P. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.01.012 · Cited by 293
Tan, T. Z., Miow, Q. H., Huang, R. Y., Wong, M. K., Ye, J., Lau, J. A., Wu, M. C., Bin Abdul Hadi, L. H., Soong, R., Choolani, M., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201201823 · Cited by 281
Coleman, R. L., Sill, M. W., Bell-McGuinn, K., Aghajanian, C., Gray, H. J., Tewari, K. S., Rubin, S. C., Rutherford, T. J., Chan, J. K., Chen, A., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.03.042 · Cited by 265
Meinhold-Heerlein, I., Fotopoulou, C., Harter, P., Kurzeder, C., Mustea, A., Wimberger, P., Hauptmann, S., & Sehouli, J. (2016) · Archives of Gynecology and Obstetrics · doi:10.1007/s00404-016-4035-8 · Cited by 261
MacLeod, Grant, Donaldson, Khan, Campbell, Daly, Lawrence, Wallace, Vale, Cody, et al. (1998) · Health Technology Assessment · doi:10.3310/hta2050 · Cited by 254
Mechanisms of chemoresistance and poor prognosis in ovarian clear cell carcinoma
Itamochi, H., Kigawa, J., & Terakawa, N. (2008) · Cancer Science · doi:10.1111/j.1349-7006.2008.00747.x · Cited by 237
Ledermann, J. A., Embleton, A. C., Raja, F., Perren, T. J., Jayson, G. C., Rustin, G. J. S., Kaye, S. B., Hirte, H., Eisenhauer, E., Vaughan, M., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01167-8 · Cited by 237
p53 as a target for the treatment of cancer
Duffy, M. J., Synnott, N. C., McGowan, P. M., Crown, J., O’Connor, D., & Gallagher, W. M. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.10.004 · Cited by 229
Kwiatkowski, D. J., Choueiri, T. K., Fay, A. P., Rini, B. I., Thorner, A. R., de Velasco, G., Tyburczy, M. E., Hamieh, L., Albiges, L., Agarwal, N., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-2631 · Cited by 228
Low‐grade serous carcinomas of the ovary contain very few point mutations
Jones, S., Wang, T., Kurman, R. J., Nakayama, K., Velculescu, V. E., Vogelstein, B., Kinzler, K. W., Papadopoulos, N., & Shih, I. (2012) · The Journal of Pathology · doi:10.1002/path.3967 · Cited by 218
Trabectedin, a drug acting on both cancer cells and the tumour microenvironment
D’Incalci, M., Badri, N., Galmarini, C. M., & Allavena, P. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.149 · Cited by 218
The PI3K/Akt/mTOR pathway in ovarian cancer: therapeutic opportunities and challenges
Cheaib, B., Auguste, A., & Leary, A. (2015) · Chinese Journal of Cancer · doi:10.5732/cjc.014.10289 · Cited by 216
Role of KRAS and BRAF gene mutations in mucinous ovarian carcinoma
Gemignani, M. L., Schlaerth, A. C., Bogomolniy, F., Barakat, R. R., Lin, O., Soslow, R., Venkatraman, E., & Boyd, J. (2003) · Gynecologic Oncology · doi:10.1016/s0090-8258(03)00264-6 · Cited by 213
Behbakht, K., Sill, M. W., Darcy, K. M., Rubin, S. C., Mannel, R. S., Waggoner, S., Schilder, R. J., Cai, K. Q., Godwin, A. K., & Alpaugh, R. K. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.06.022 · Cited by 211
Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes
Hunter, S. M., Australian Ovarian Cancer Study Group, Anglesio, M. S., Ryland, G. L., Sharma, R., Chiew, Y.-E., Rowley, S. M., Doyle, M. A., Li, J., Gilks, C. B., et al. (2015) · Oncotarget · doi:10.18632/oncotarget.5438 · Cited by 202
Anglesio, M. S., Kommoss, S., Tolcher, M. C., Clarke, B., Galletta, L., Porter, H., Damaraju, S., Fereday, S., Winterhoff, B. J., Kalloger, S. E., et al. (2013) · The Journal of Pathology · doi:10.1002/path.4088 · Cited by 198
Pinsky, P. F., Yu, K., Kramer, B. S., Black, A., Buys, S. S., Partridge, E., Gohagan, J., Berg, C. D., & Prorok, P. C. (2016) · Gynecologic Oncology · doi:10.1016/j.ygyno.2016.08.334 · Cited by 191
Makhija, S., Amler, L. C., Glenn, D., Ueland, F. R., Gold, M. A., Dizon, D. S., Paton, V., Lin, C.-Y., Januario, T., Ng, K., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.3354 · Cited by 186
Catasús, L., Bussaglia, E., Rodrı́guez, I., Gallardo, A., Pons, C., Irving, J. A., & Prat, J. (2004) · Human Pathology · doi:10.1016/j.humpath.2004.07.019 · Cited by 181
Clinical relevance of circulating cell-free microRNAs in ovarian cancer
Nakamura, K., Sawada, K., Yoshimura, A., Kinose, Y., Nakatsuka, E., & Kimura, T. (2016) · Molecular Cancer · doi:10.1186/s12943-016-0536-0 · Cited by 180
Mackenzie, R., Kommoss, S., Winterhoff, B. J. N., Kipp, B. R., García, J. J., Voss, J. S., Halling, K. C., Karnezis, A. N., Senz, J., Yang, W., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1421-8 · Cited by 172
Vang, R., Levine, D. A., Soslow, R. A., Zaloudek, C., Shih, I.-M., & Kurman, R. J. (2016) · International Journal of Gynecological Pathology · doi:10.1097/pgp.0000000000000207 · Cited by 170
Nanotechnology approaches for personalized treatment of multidrug resistant cancers
Minko, T., Rodríguez-Rodríguez, L., & Pozharov, V. P. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.017 · Cited by 169
Immune checkpoint inhibition in ovarian cancer
Hamanishi, J., Mandai, M., & Konishi, I. (2016) · International Immunology · doi:10.1093/intimm/dxw020 · Cited by 169
Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors
Australian Ovarian Cancer Study Group, Ryland, G. L., Hunter, S. M., Doyle, M. A., Caramia, F., Li, J., Rowley, S. M., Christie, M., Allan, P. E., Stephens, A. N., et al. (2015) · Genome Medicine · doi:10.1186/s13073-015-0210-y · Cited by 164
Biomarkers for Immunotherapy: Current Developments and Challenges
Spencer, K. R., Wang, J., Silk, A. W., Ganesan, S., Kaufman, H. L., & Mehnert, J. M. (2016) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_160766 · Cited by 160
Self-citationGenomic Analysis Reveals the Molecular Heterogeneity of Ovarian Clear Cell Carcinomas
Tan, D. S. P., Iravani, M., McCluggage, W. G., Lambros, M. B. K., Milanezi, F., Mackay, A. G., Gourley, C., Geyer, F. C., Vatcheva, R., Millar, J., et al. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1688 · Cited by 158
Catenacci, D. V. T. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.09.011 · Cited by 150
Alternate molecular genetic pathways in ovarian carcinomas of common histological types
Willner, J. B., Wurz, K., Allison, K. H., Galic, V., Garcia, R. L., Goff, B. A., & Swisher, E. M. (2007) · Human Pathology · doi:10.1016/j.humpath.2006.10.007 · Cited by 135
Bagnoli, M., Canevari, S., Califano, D., Losito, S., Maïo, M. D., Raspagliesi, F., Carcangiu, M. L., Toffoli, G., Cecchin, E., Sorio, R., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30108-5 · Cited by 128
García, A. A., Sill, M. W., Lankes, H. A., Godwin, A. K., Mannel, R. S., Armstrong, D. K., Carolla, R. L., Liepman, M. K., Spirtos, N. M., Fischer, E. G., et al. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.10.022 · Cited by 125
Gourley, C., McCavigan, A., Perren, T. J., Paul, J., Michie, C. O., Churchman, M., Williams, A. R. W., McCluggage, W. G., Parmar, M., Kaplan, R. S., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.5502 · Cited by 123
Cowin, P. A., George, J., Fereday, S., Loehrer, E. A., Loo, P. V., Cullinane, C. M., Etemadmoghadam, D., Ftouni, S., Galletta, L., Anglesio, M. S., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-12-0203 · Cited by 120
Auersperg, N. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.03.021 · Cited by 120
Leijen, S., Beijnen, J. H., & Schellens, J. H. M. (2010) · Current Clinical Pharmacology · doi:10.2174/157488410791498824 · Cited by 112
Husseinzadeh, N., & Husseinzadeh, H. D. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.02.017 · Cited by 111
Clonal evolution of high‐grade serous ovarian carcinoma from primary to recurrent disease
Castellarin, M. L., Milne, K., Zeng, T., Tse, K., Mayo, M., Zhao, Y., Webb, J. R., Watson, P. H., Nelson, B. H., & Holt, R. A. (2012) · The Journal of Pathology · doi:10.1002/path.4105 · Cited by 106
Identifying microRNA/mRNA dysregulations in ovarian cancer
Miles, G. D., Seiler, M., Rodriguez, L., Rajagopal, G., & Bhanot, G. (2012) · BMC Research Notes · doi:10.1186/1756-0500-5-164 · Cited by 101
Pepa, C. D., Tonini, G., Santini, D., Losito, S., Pisano, C., Napoli, M. D., Cecere, S. C., Gargiulo, P., & Pignata, S. (2014) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2014.12.003 · Cited by 99
Efficient molecular subtype classification of high‐grade serous ovarian cancer
Leong, H. S., Galletta, L., Etemadmoghadam, D., George, J., Study, T. A. O. C., Köbel, M., Ramus, S. J., & Bowtell, D. D. L. (2015) · The Journal of Pathology · doi:10.1002/path.4536 · Cited by 95
Lee, J., Yoon, J.-K., Kim, B., Kim, S., Kim, M. A., Lim, H., Bang, D., & Song, Y. S. (2015) · BMC Cancer · doi:10.1186/s12885-015-1077-4 · Cited by 92
Ross, J. S., Ali, S. M., Wang, K., Palmer, G. A., Yelensky, R., Lipson, D., Miller, V. A., Zajchowski, D. A., Shawver, L. K., & Stephens, P. J. (2013) · Gynecologic Oncology · doi:10.1016/j.ygyno.2013.06.019 · Cited by 90
Zhou, Q., Li, W., Leng, B., Zheng, W., He, Z., Zuo, M., & Chen, A. (2016) · PLoS ONE · doi:10.1371/journal.pone.0155495 · Cited by 90
Genomic and transcriptomic plasticity in treatment-naïve ovarian cancerPreprint
Hoogstraat, M., de Pagter, M. S., Cirkel, G. A., van Roosmalen, M. J., Harkins, T. T., Duran, K. J., Kreeftmeijer, J., Renkens, I., Witteveen, P. O., Lee, C. C., et al. (2013) · Genome Research · doi:10.1101/gr.161026.113 · Cited by 86
Opportunities in immunotherapy of ovarian cancer
Coukos, G., Tanyi, J. L., & Kandalaft, L. E. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw084 · Cited by 85
Ferriss, J. S., Java, J., Bookman, M. A., Fleming, G. F., Monk, B. J., Walker, J. L., Homesley, H. D., Fowler, J. M., Greer, B. E., Boente, M. P., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.07.103 · Cited by 83
Emons, G., Kurzeder, C., Schmalfeldt, B., Neuser, P., de Gregorio, N., Pfisterer, J., Park‐Simon, T., Mahner, S., Schroder, W., Lück, H., et al. (2015) · Gynecologic Oncology · doi:10.1016/j.ygyno.2015.12.025 · Cited by 75
Dynamic Modeling and Analysis of the Cross-Talk between Insulin/AKT and MAPK/ERK Signaling Pathways
Arkun, Y. (2016) · PLoS ONE · doi:10.1371/journal.pone.0149684 · Cited by 73
Traver, S., Assou, S., Scalici, E., Haouzi, D., Al-Edani, T., Belloc, S., & Hamamah, S. (2014) · Human Reproduction Update · doi:10.1093/humupd/dmu031 · Cited by 72
Targeting HER2 in ovarian and uterine cancers: Challenges and future directions
Teplinsky, E., & Muggia, F. M. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.09.003 · Cited by 70
Immune Checkpoint Inhibitors: A New Opportunity in the Treatment of Ovarian Cancer?
Mittica, G., Genta, S., Aglietta, M., & Valabrega, G. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17071169 · Cited by 70
Barrett, C. L., DeBoever, C., Jepsen, K., Saenz, C. C., Carson, D. A., & Frazer, K. A. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1508057112 · Cited by 69
Molecular Characterization of 103 Ovarian Serous and Mucinous Tumors
Vereczkey, I., Serester, O., Dobos, J., Gallai, M., Szakács, O., Szentirmay, Z., & Tóth, E. (2010) · Pathology & Oncology Research · doi:10.1007/s12253-010-9345-8 · Cited by 68
Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus
Lim, S. M., Park, H. S., Kim, S., Kim, S., Ali, S. M., Greenbowe, J. R., Yang, I. S., Kwon, N., Lee, J., Ryu, M., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7234 · Cited by 68
Harnessing Pandemonium: The Clinical Implications of Tumor Heterogeneity in Ovarian Cancer
Blagden, S. P. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00149 · Cited by 66
Monk, B. J., Ghatage, P., Parekh, T. V., Henitz, E. D., Knoblauch, R. E., Matos-Pita, A. S., Nieto, A., Park, Y. C., Cheng, P. S., Li, W., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv071 · Cited by 66
Genetic heterogeneity after first-line chemotherapy in high-grade serous ovarian cancer
Lambrechts, S., Smeets, D., Moisse, M., Braicu, E. I., Vanderstichele, A., Zhao, H., Nieuwenhuysen, E. V., Berns, E. M. J. J., Sehouli, J., Zeillinger, R., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.001 · Cited by 61
Differential role of microRNAs in prognosis, diagnosis, and therapy of ovarian cancer
Mahdian-shakib, A., Dorostkar, R., Tat, M., Hashemzadeh, M. S., & Saidi, N. (2016) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2016.09.087 · Cited by 61
Beltrame, L., Marino, M. D., Fruscio, R., Calura, E., Chapman, B., Clivio, L., Sina, F. P., Mele, C., Iatropoulos, P., Grassi, T., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv164 · Cited by 54
WEE1 Kinase As a Target for Cancer Therapy
Mueller, S., & Haas-Kogan, D. A. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.62.2290 · Cited by 53
Zeppernick, F. A., Meinhold-Heerlein, I. M., & Shih, I. (2014) · Journal of obstetrics and gynaecology research · doi:10.1111/jog.12550 · Cited by 47
Emerging therapies: angiogenesis inhibitors for ovarian cancer
Jackson, A. L., Eisenhauer, E. L., & Herzog, T. J. (2015) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2015.1036739 · Cited by 37
Oza, A. M., Weberpals, J. I., Provencher, D. M., Grischke, E., Hall, M., Uyar, D. S., Estevez-Diz, M. D. P., Marmé, F., Kuzmin, A., Rosenberg, P., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.33.15_suppl.5506 · Cited by 35
Paracchini, L., Mannarino, L., Craparotta, I., Romualdi, C., Fruscio, R., Grassi, T., Fotia, V., Caratti, G., Perego, P., Calura, E., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10505 · Cited by 30
Pertuzumab for the treatment of ovarian cancer
Langdon, S. P., Faratian, D., Nagumo, Y., Mullen, P., & Harrison, D. J. (2010) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2010.487062 · Cited by 29
The search for biomarkers to direct antiangiogenic treatment in epithelial ovarian cancer
Secord, A. A., Nixon, A. B., & Hurwitz, H. I. (2014) · Gynecologic Oncology · doi:10.1016/j.ygyno.2014.08.033 · Cited by 29
What Is the Place of PARP Inhibitors in Ovarian Cancer Treatment?
Liu, J. F., & Matulonis, U. A. (2016) · Current Oncology Reports · doi:10.1007/s11912-016-0515-z · Cited by 27
Calura, E., Paracchini, L., Fruscio, R., DiFeo, A. V., Ravaggi, A., Peronne, J., Martini, P. G. V., Sales, G., Beltrame, L., Bignotti, E., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw210 · Cited by 27
DNA Damage Signaling and Apoptosis in Preinvasive Tubal Lesions of Ovarian Carcinoma
Chene, G., Ouellet, V., Rahimi, K., Barrès, V., Caceres, K., Meunier, L., Cyr, L., de Ladurantaye, M., Provencher, D. M., & Mes‐Masson, A. (2014) · International Journal of Gynecological Cancer · doi:10.1097/igc.0000000000000196 · Cited by 18
Cited by
Cell Origins of High-Grade Serous Ovarian Cancer
Kim, J., Park, E., Kim, O., Schilder, J., Coffey, D., Cho, C.-H., & Bast, R. (2018) · Cancers · doi:10.3390/cancers10110433 · Cited by 264
Natural and synthetic compounds in Ovarian Cancer: A focus on NRF2/KEAP1 pathway
Tossetta, G., & Marzioni, D. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106365 · Cited by 115
Metadata
- Authors
- Rojas, V., Hirshfield, K., Ganesan, S., & Rodriguez-Rodriguez, L.
- Venue
- International Journal of Molecular Sciences
- Publisher
- MDPI AG
- Published
- 2016-12-15
- Volume
- 17
- Issue
- 12
- Pages
- 2113
- ISSN
- 1422-0067 (ISSN-L)
- OpenAlex
- W2561717201
- Cited by
- 254
- References
- 115
- FWCI
- 21.73
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.